Ionis Pharmaceuticals (IONS) News Today $32.47 -0.98 (-2.93%) As of 01:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period JPMorgan Chase & Co. Cuts Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $45.00JPMorgan Chase & Co. decreased their target price on shares of Ionis Pharmaceuticals from $47.00 to $45.00 and set a "neutral" rating for the company in a research report on Monday.March 25 at 8:54 AM | marketbeat.comIonis Pharmaceuticals price target lowered to $45 from $47 at JPMorganMarch 24 at 5:15 PM | markets.businessinsider.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Recommendation of "Moderate Buy" by BrokeragesIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold raMarch 24 at 2:23 AM | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Position Boosted by Swiss National BankSwiss National Bank raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 8.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 279,200 shares of the company's stock after acquiring an additional 2March 23 at 3:44 AM | marketbeat.comProficio Capital Partners LLC Makes New $829,000 Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Proficio Capital Partners LLC purchased a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 23,703 shares of the company's stock, valued at approximately $829,000. Several other heMarch 23 at 3:09 AM | marketbeat.comSector Gamma AS Has $8.25 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Sector Gamma AS lifted its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 235,842 shares of the company's stock after buying an additional 25,000 shares duringMarch 22 at 6:51 AM | marketbeat.comPrivium Fund Management B.V. Has $9.33 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Privium Fund Management B.V. grew its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 6.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 266,794 shares of theMarch 20, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Stock Rating Upgraded by StockNews.comMarch 20, 2025 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Upgraded at StockNews.comStockNews.com raised Ionis Pharmaceuticals to a "sell" rating in a research note on Tuesday.March 19, 2025 | marketbeat.comMetagenomi price target lowered to $20 from $25 at Wells FargoMarch 18, 2025 | markets.businessinsider.comNikko Asset Management Americas Inc. Has $5.47 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Nikko Asset Management Americas Inc. cut its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 20.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 156,657 shares of the company's stock after seMarch 18, 2025 | marketbeat.comTocqueville Asset Management L.P. Has $12.31 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Tocqueville Asset Management L.P. cut its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 13.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 352,140 shares ofMarch 18, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $4.38 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 606.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 125,March 17, 2025 | marketbeat.comWilliam Blair Has Optimistic Outlook of IONS Q1 EarningsMarch 16, 2025 | americanbankingnews.comQ1 EPS Estimate for Ionis Pharmaceuticals Lifted by AnalystIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Stock analysts at William Blair raised their Q1 2026 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a note issued to investors on Wednesday, March 12th. William Blair analyst M. Minter now forecasts that the compMarch 15, 2025 | marketbeat.comEssential Planning LLC. Takes $428,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Essential Planning LLC. purchased a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 11,440 shares of the company's stock, valued at approximately $4March 14, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 38,420 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Charles Schwab Investment Management Inc. increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 2.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor ownedMarch 14, 2025 | marketbeat.comJPMorgan Chase & Co. Cuts Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $47.00JPMorgan Chase & Co. reduced their price target on shares of Ionis Pharmaceuticals from $51.00 to $47.00 and set a "neutral" rating for the company in a research report on Tuesday.March 12, 2025 | marketbeat.comIonis Pharmaceuticals (IONS) Receives a Buy from William BlairMarch 12, 2025 | markets.businessinsider.comIonis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million DealMarch 12, 2025 | finance.yahoo.comIonis Pharmaceuticals and Ono announce license agreement for sapablursenMarch 11, 2025 | markets.businessinsider.comIonis and Ono announce global license agreement for sapablursen in polycythemia veraMarch 11, 2025 | businesswire.comOno Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia VeraMarch 11, 2025 | businesswire.comIonis and AstraZeneca’s WAINZUA gets EU approval for ATTRv-PN treatmentMarch 10, 2025 | markets.businessinsider.comInceptionr LLC Buys Shares of 14,390 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Inceptionr LLC acquired a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 14,390 shares of the company's stock, valuedMarch 9, 2025 | marketbeat.com23,703 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Bought by Proficio Capital Partners LLCProficio Capital Partners LLC bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,703 sharesMarch 9, 2025 | marketbeat.comCandriam S.C.A. Reduces Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Candriam S.C.A. lowered its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 10.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 849,824 shares of the company's stockMarch 7, 2025 | marketbeat.comY Intercept Hong Kong Ltd Trims Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Y Intercept Hong Kong Ltd cut its position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 53.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 9,407 shares of the company's stock afteMarch 4, 2025 | marketbeat.comFY2026 Earnings Estimate for IONS Issued By Leerink PartnrsIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Stock analysts at Leerink Partnrs reduced their FY2026 earnings per share estimates for shares of Ionis Pharmaceuticals in a report issued on Monday, February 24th. Leerink Partnrs analyst M. Foroohar now anticipates that the company willFebruary 28, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Consensus Rating of "Moderate Buy" from BrokeragesIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) has received an average rating of "Moderate Buy" from the twenty ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have issued aFebruary 27, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by ARK Investment Management LLCARK Investment Management LLC decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 25.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,025,260 shares of the cFebruary 26, 2025 | marketbeat.comIonis to present at upcoming investor conferencesFebruary 25, 2025 | businesswire.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Patrick R. O'neil Sells 1,207 SharesIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Patrick R. O'neil sold 1,207 shares of Ionis Pharmaceuticals stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $32.35, for a total transaction of $39,046.45. Following the completion of the transaction, the executive vice president now owns 56,245 shares of the company's stock, valued at $1,819,525.75. This represents a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.February 24, 2025 | marketbeat.comC WorldWide Group Holding A S Has $13.98 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)C WorldWide Group Holding A S boosted its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 33.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 400,000 shares of the company's stock after buying an additionalFebruary 24, 2025 | marketbeat.comWhat is William Blair's Estimate for IONS Q1 Earnings?Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Ionis Pharmaceuticals in a research report issued on Wednesday, February 19th. William Blair analyst M. Minter forecasts that the company wilFebruary 24, 2025 | marketbeat.comQ1 Earnings Forecast for IONS Issued By Leerink PartnrsIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for Ionis Pharmaceuticals in a research note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst M. Foroohar forecasts that the company willFebruary 24, 2025 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Purchased by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D lifted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 22.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 63,206 shares of the company's stockFebruary 22, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $64.00 by Analysts at CitigroupCitigroup decreased their price target on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday.February 21, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Given Outperform Rating at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and issued a $70.00 price objective on shares of Ionis Pharmaceuticals in a research note on Thursday.February 21, 2025 | marketbeat.comBMO Capital Markets Has Lowered Expectations for Ionis Pharmaceuticals (NASDAQ:IONS) Stock PriceBMO Capital Markets decreased their target price on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating for the company in a research report on Thursday.February 21, 2025 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Ionis Pharmaceuticals (NASDAQ:IONS)Needham & Company LLC reissued a "buy" rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday.February 21, 2025 | marketbeat.comIonis Pharmaceuticals price target lowered to $63 from $65 at BofAFebruary 21, 2025 | markets.businessinsider.comIonis Pharmaceuticals price target lowered to $60 from $61 at Raymond JamesFebruary 21, 2025 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up on Earnings BeatIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up Following Better-Than-Expected EarningsFebruary 20, 2025 | marketbeat.comIonis Pharmaceuticals price target lowered to $64 from $67 at CitiFebruary 20, 2025 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Posts Quarterly Earnings Results, Beats Estimates By $0.43 EPSIonis Pharmaceuticals (NASDAQ:IONS - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.43. Ionis Pharmaceuticals had a negative net margin of 44.58% and a negative return on equity of 88.98%. During the same quarter last year, the company earned $0.12 earnings per share.February 20, 2025 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Issues Earnings ResultsIonis Pharmaceuticals (NASDAQ:IONS - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.43. Ionis Pharmaceuticals had a negative return on equity of 88.98% and a negative net margin of 44.58%. During the same period last year, the company earned $0.12 earnings per share.February 20, 2025 | marketbeat.comIonis Pharmaceuticals trading halted, volatility trading pauseFebruary 19, 2025 | markets.businessinsider.comIonis posts Q4 beat as revenue base widensFebruary 19, 2025 | msn.comIonis Pharmaceuticals price target lowered to $38 from $45 at StifelFebruary 19, 2025 | markets.businessinsider.com Remove Ads Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.860.63▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼107▲IONS Articles Average Week Remove Ads Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today BMRN News Today INCY News Today NBIX News Today EXEL News Today EXAS News Today RGEN News Today HALO News Today MDGL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IONS Stock Free IONS Stock Alerts